Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Eli Lilly's experimental combination drug EloraTZP led to an average body weight loss of 23.3% over 48 weeks in a mid-stage trial, compared to 14.8% for its blockbuster Zepbound alone. The company plans to start late-stage trials for EloraTZP in the fourth quarter of 2026.
Bagsværd, Denmark, 30 September 2026 — Novo Nordisk today announced new data on how CagriSema works inside both the brain and body, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026.In a 52-week functional magnetic resonance imaging (fMRI) study, a brain sca…
A 194-patient real-world study presented at a diabetes meeting found patients who switched from injectable obesity drugs to oral semaglutide lost an average 4.1% of body weight in three months. Novo said the data support the Wegovy pill as it competes with Eli Lilly in oral obesity treatments.
Novo Nordisk said a real-world study of 636,525 adults with type 2 diabetes found escalated-dose Ozempic 2 mg had a statistically significant 6% lower risk of major adverse cardiovascular events versus switching to Mounjaro doses up to 15 mg, with results presented at the EASD meeting in Milan.
Novo Nordisk said it will present obesity and diabetes data from its Wegovy pill and next-generation treatments at a major European medical conference, as Eli Lilly readies its own obesity updates.